511 related articles for article (PubMed ID: 9862847)
1. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
2. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
[TBL] [Abstract][Full Text] [Related]
3. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
Poupon RE; Bonnand AM; Chrétien Y; Poupon R
Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
5. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
8. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
9. Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?
Kilmurry MR; Heathcote EJ; Cauch-Dudek K; O'Rourke K; Bailey RJ; Blendis LM; Ghent CN; Minuk GY; Pappas SC; Scully LJ; Steinbrecher UP; Sutherland LR; Williams CN; Worobetz LJ
Hepatology; 1996 May; 23(5):1148-53. PubMed ID: 8621147
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.
Pasha T; Heathcote J; Gabriel S; Cauch-Dudek K; Jorgensen R; Therneau T; Dickson ER; Lindor KD
Hepatology; 1999 Jan; 29(1):21-6. PubMed ID: 9862844
[TBL] [Abstract][Full Text] [Related]
11. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
Batts KP; Jorgensen RA; Dickson ER; Lindor KD
Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice.
Pelletier G; Roulot D; Davion T; Masliah C; Causse X; Oberti F; Raabe JJ; Van Lemmens C; Labadie H; Serfaty L;
Hepatology; 2003 Apr; 37(4):887-92. PubMed ID: 12668982
[TBL] [Abstract][Full Text] [Related]
13. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
[TBL] [Abstract][Full Text] [Related]
14. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
Jorgensen R; Angulo P; Dickson ER; Lindor KD
Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454
[TBL] [Abstract][Full Text] [Related]
15. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results.
Kaplan MM; Cheng S; Price LL; Bonis PA
Hepatology; 2004 Apr; 39(4):915-23. PubMed ID: 15057894
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
18. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD
Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447
[TBL] [Abstract][Full Text] [Related]
19. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
20. Natural history of pruritus in primary biliary cirrhosis.
Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
